Dow Down0.17% Nasdaq Down0.28%

Insmed Incorporated (INSM)

13.05 Down 0.46(3.40%) Sep 30, 4:00PM EDT
|After Hours : 13.05 Up 0.00 (0.03%) Sep 30, 4:39PM EDT
ProfileGet Profile for:
Insmed Incorporated
9 Deer Park Drive
Suite C
Monmouth Junction, NJ 08852
United States - Map
Phone: 732-997-4600

Index Membership:N/A
Full Time Employees:61

Business Summary 

Insmed Incorporated, a biopharmaceutical company, focuses on developing and commercializing inhaled therapies for patients with serious lung diseases. Its lead product candidate is ARIKAYCE, an inhaled antibiotic treatment that delivers a proven and potent anti-infective directly to the site of serious lung infections. The company’s ARIKAYCE is in Phase II clinical trial for patients with lung infections caused by non-tuberculous mycobacteria (NTM) in the United States and Canada; and completed a Phase III clinical trial in Europe and Canada for cystic fibrosis (CF) patients who have lung infections caused by Pseudomonas aeruginosa. Insmed Incorporated was founded in 1999 and is headquartered in Monmouth Junction, New Jersey.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Insmed Incorporated

Corporate Governance 
Insmed Incorporated’s ISS Governance QuickScore as of Sep 1, 2014 is 10. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 9; Compensation: 10.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. William H. Lewis , 45
Chief Exec. Officer, Pres and Director
Mr. Andrew T. Drechsler , 42
Chief Financial Officer and Principal Accounting Officer
Ms. Christine A. Pellizzari , 46
Gen. Counsel and Corp. Sec.
Dr. Renu Gupta M.D., 59
Special Advisor To Chief Exec. Officer
Mr. Walter Perkins Ph.D.,
Chief Technology Officer
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders